Tezepelumab

New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease

Retrieved on: 
일요일, 5월 19, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Patient, Lung, AMG, Rheumatology, Biopharmaceutical, Immunology, Risk, Heart, Allergy, Conditional sentence, Disease, Safety, Asthma, Bronchitis, Tezepelumab, Dermatology, Hospital, Death, Growth, TSLP, Eosinophilic, COPD, Emphysema, Chronic obstructive pulmonary disease, Mortality, Inflammation, AstraZeneca, Gastroenterology, Pharmaceutical industry

Patients received tezepelumab 420 mg, or placebo, administered via subcutaneous injection at the trial site every four weeks over a 52-week treatment period.

Key Points: 
  • Patients received tezepelumab 420 mg, or placebo, administered via subcutaneous injection at the trial site every four weeks over a 52-week treatment period.
  • Both companies will continue to share costs and profits equally after payment by AstraZeneca of a mid single-digit inventor royalty to Amgen.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
수요일, 5월 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Retrieved on: 
화요일, 4월 16, 2024
Fetus, AMGN, American Thoracic Society, Congress, Arthralgia, ATS, Chronic obstructive pulmonary disease, Emphysema, Pregnancy, Infection, Tezepelumab, PDT, Allergic conjunctivitis, Amgen, Research and development, Back pain, Conference, Placentalia, Vaccine, Miscarriage, Development, Ageing, Helminthiasis, Incidence, Patient, Anaphylaxis, Hypersensitivity, Rash, Pharyngitis, Birth, Asthma, Bronchitis, AstraZeneca, Excipient, Pharmaceutical industry

THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. 

Key Points: 
  • Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17% (90% CI: −6, 36; p=0.1042).
  • Of note, more reductions were observed in a prespecified subgroup of patients with BEC ≥150 cells/μL (37% [95% CI: 7, 57]).
  • The trend in reduction was greater in a small number of subjects with BEC ≥300 cells/µL.
  • We look forward to presenting the full data set at the congress and based on these findings, we are actively planning for the Phase 3 development of tezepelumab in COPD.

Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients

Retrieved on: 
목요일, 3월 7, 2024
Health, Other Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, EOS, TSLP, Polyp (medicine), Sinusitis, Inflammation, Upstream, Asthma, Biomarker, VALIANT, Patient, Clinical trial, Tezepelumab, Nitric acid, Pharmaceutical industry

Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the dosing of the first patients in its Phase 2 VALIANT clinical trial of verekitug (UPB-101) in patients with severe asthma.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the dosing of the first patients in its Phase 2 VALIANT clinical trial of verekitug (UPB-101) in patients with severe asthma.
  • Verekitug is a recombinant fully human immunoglobulin G1 monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation.
  • Verekitug is currently under investigation in a Phase 2 study for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
  • The study will evaluate verekitug’s efficacy in the treatment of severe asthma as reflected by the registrational primary endpoint of the annual asthma exacerbation rate (AAER).

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
목요일, 12월 7, 2023
Pressure, Nonsteroidal anti-inflammatory drug, Polyp (medicine), AstraZeneca, Inflammation, Face, Budesonide, Omalizumab, CRS, Eosinophilic granulomatosis with polyangiitis, Disease, Network congestion, PROPEL, Sleep apnea, Patient, Snoring, EU4, Sinusitis, Polyp, Allergic rhinitis, Fluticasone, Endoscopy, Smell, Nasal administration, Aspirin, Ibuprofen, Diagnosis, Cystic fibrosis, Tezepelumab, Risk, Growth, Glucocorticoid, Recurrence, Rhinorrhea, Mometasone, Physician, Asthma, LAS, Taste, GSK plc, Paranasal sinuses, Amgen, Pharmaceutical industry, Nursing

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
목요일, 12월 7, 2023
Pressure, Nonsteroidal anti-inflammatory drug, Polyp (medicine), AstraZeneca, Inflammation, Face, Budesonide, Omalizumab, CRS, Eosinophilic granulomatosis with polyangiitis, Disease, Network congestion, PROPEL, Sleep apnea, Patient, Snoring, EU4, Sinusitis, Polyp, Allergic rhinitis, Fluticasone, Endoscopy, Smell, Nasal administration, Aspirin, Ibuprofen, Diagnosis, Cystic fibrosis, Tezepelumab, Risk, Growth, Glucocorticoid, Recurrence, Rhinorrhea, Mometasone, Physician, Asthma, LAS, Taste, GSK plc, Paranasal sinuses, Amgen, Pharmaceutical industry, Nursing

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN

Retrieved on: 
목요일, 2월 2, 2023
Caregiver, Vaccine, Helminthiasis, Tezepelumab, Ageing, Allergy, Rash, Asthma and Allergy Foundation of America, Medicine, Placentalia, Pharyngitis, Phenotype, Maintenance, Excipient, Patient, Incidence, Asthma, Back pain, Pregnancy, Fetus, Food, Severe cutaneous adverse reactions, Hypersensitivity, Allergic conjunctivitis, Amgen, Birth, FDA, Infection, AMGN, Miscarriage, AstraZeneca, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Anaphylaxis, European, Arthralgia, Acute exacerbation of chronic obstructive pulmonary disease, Pharmaceutical industry, Dietary supplement, EU

THOUSAND OAKS, Calif., Feb. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.1 First approved by the FDA in December 2021, TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g., eosinophilic or allergic) or biomarker limitation within its approved label.2-9

Key Points: 
  • "We believe self-administration alternatives can play an important role in patients' lives and address unmet needs for those living with severe asthma."
  • TEZSPIRE is currently approved for the treatment of severe asthma in the U.S., EU, Japan and other countries.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • Hypersensitivity reactions were observed in the clinical trials (e.g., rash and allergic conjunctivitis) following the administration of TEZSPIRE.

Renibus Therapeutics Strengthens Leadership Team with Asha Ramdas as SVP, Program Management, Technical Operations and Manufacturing

Retrieved on: 
화요일, 12월 13, 2022
Therapy, Johnson & Johnson, Tezepelumab, End organ damage, Pneumonia, Food, Regulation of tobacco by the U.S. Food and Drug Administration, RCT, Asha, Patient, Global production network, NASH, Polymer chemistry, Commercialization, CKD, HIV disease progression rates, CMC, Program management, SVP, Asthma, Iron(II) sulfide, Geron Corporation, Atomic mass, Ram Dass, SNPP, Mount Holyoke College, Risk, Pharmaceutical industry, Chemistry, Amgen, COVID

SOUTHLAKE, Texas, Dec. 13, 2022 /PRNewswire/ -- Renibus Therapeutics, Inc., ("Renibus"), a clinical-stage biotechnology company developing breakthrough products for cardiorenal diseases, today announced the appointment of Asha Ramdas as SVP, Program Management, Technical Operations and Manufacturing. Ms. Ramdas brings over twenty-five years of biopharma leadership experience to Renibus, with a strong track record in delivering high-impact products to the market.

Key Points: 
  • -Ms. Ramdas has more than 25 years of healthcare experience, including at Amgen and Johnson & Johnson-
    SOUTHLAKE, Texas, Dec. 13, 2022 /PRNewswire/ -- Renibus Therapeutics, Inc., ("Renibus"), a clinical-stage biotechnology company developing breakthrough products for cardiorenal diseases, today announced the appointment of Asha Ramdas as SVP, Program Management, Technical Operations and Manufacturing.
  • Ms. Ramdas brings over twenty-five years of biopharma leadership experience to Renibus, with a strong track record in delivering high-impact products to the market.
  • "We are thrilled to welcome Asha to the Renibus executive team," said Frank Stonebanks, CEO of Renibus.
  • Asha joins Renibus from Amgen, where she spent nine years in various senior leadership roles, most recently as Vice President, Commercialization, Program and Portfolio Management.

Tezepelumab Reduces Asthma Exacerbations in Patients with Severe, Uncontrolled Asthma Regardless of Season

Retrieved on: 
월요일, 2월 7, 2022
Maintenance, Food and Drug Administration Amendments Act of 2007, Research, American Academy of Allergy, Asthma, and Immunology, Flavia, Asthma, FDA, Patient, AAAAI, Phenotype, American Academy, The Journal of Allergy and Clinical Immunology, Season, Tezepelumab, Food, MD, Allergist, Journal, Pharmaceutical industry, Dairy product, Allergy, Immunology

"This promising data confirms that tezepelumab is effective not only regardless of asthma phenotype, but also regardless of the season.

Key Points: 
  • "This promising data confirms that tezepelumab is effective not only regardless of asthma phenotype, but also regardless of the season.
  • For patients with uncontrolled, severe asthma, it is vital to have effective medications that can improve symptoms at all times of year."
  • Researchers examined the annualized asthma exacerbation rate (AAER) and number of patients without exacerbations on a season by season basis.
  • April Presnell, The American Academy of Allergy, Asthma & Immunology, (414) 272-6071, [email protected]
    SOURCE The American Academy of Allergy, Asthma & Immunology

Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report

Retrieved on: 
월요일, 1월 10, 2022
Health, Access, Alzheimer's disease, Eli Lilly, AMD, LinkedIn, COVID-19 vaccine, Monoclonal antibody, COVID, DME, List of life sciences, CRC, Solution, Ophthalmology, Diabetes, Medicine, FDA, Population, Alnylam Pharmaceuticals, Roche, Colorectal cancer, Standard of care, Chugai Pharmaceutical Co., Heart, Science, Incidence, Amgen, RNA, Company, Donanemab, CRISPR, AstraZeneca, Weight loss, RNA transfection, Clinical trial, Intelligence, KRAS, Drug discovery, Patient, Industry, Asthma, AD, Success rate, Patent, Research, NYSE, Artificial intelligence, Clarivate, COVID-19, Intellectual property, Machine learning, Invention, Faricimab, Data, Biogen, R, ATTR, Roy Taylor (scientist), Diabetic retinopathy, Report, T2DM, Pharmaceutical industry, Medical device, Tezepelumab

LONDON, Jan. 10, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual Drugs to Watch™ report, identifying drugs entering the market or launching key indications in 2022 which are predicted to achieve blockbuster status by 2026.  Leveraging Clarivate data and insights, analysts identified seven late-stage experimental treatments that they forecast will deliver annual sales of more than $1 billion within five years. These treatments span a remarkably diverse set of therapeutic areas, from conditions like Alzheimer's disease (AD), asthma and type 2 diabetes mellitus (T2DM), which afflict tens of millions of patients worldwide, to rare diseases, such as transthyretin amyloidosis (ATTR), among others.

Key Points: 
  • Leveraging Clarivate data and insights, analysts identified seven late-stage experimental treatments that they forecast will deliver annual sales of more than $1 billion within five years.
  • In addition, the report examines blockbuster drugs and biologics facing generic competition due to U.S. patent expirys in 2022.
  • The Drugs to Watch report highlights experimental treatments with great promise to realize improved patient outcomes and efforts to finance the next generation of innovative medicines.
  • For more Drugs to Watch updates and analyses throughout the year, visit the Drugs to Watch web page andfollow Clarivate for Life Sciences & Healthcare Twitter and LinkedIn .